TrialInvestigational new drugs2018

A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-β.

Clinton Yam et al.PubMed ↗Publisher ↗

No numbers read from the abstract.